Evidence map›Paper›PMID 42068005›Full record

ArticleAndrology2026

Low Free Testosterone Is Independently Associated With Long-Term Mortality in Men With Chronic Spinal Cord Injury.

D Tienforti, L Spagnolo, C Moretto, G Terrana, R Di Geronimo, E Perfetto, G Felzani, M G Baroni, A Barbonetti

Abstract read
In one paragraph

Article in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

D TienfortiAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-9359-7955
L SpagnoloAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
C MorettoAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
G TerranaAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
R Di GeronimoAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
E PerfettoAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
G FelzaniSpinal Unit, San Raffaele Sulmona Institute, Sulmona, Italy.
M G BaroniAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
A BarbonettiAndrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-6888-9585

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTestosterone deficiency is highly prevalent in men with chronic spinal cord injury (SCI) and is associated with obesity, sarcopenia, systemic inflammation, and metabolic dysfunction. However, the independent prognostic role of low testosterone in long-term mortality in this population remains unclear.

objectivesTo investigate whether baseline calculated free testosterone (cFT) independently predicts all-cause mortality in men with chronic SCI. MATERIALS AND

methodsWe conducted a retrospective cohort study including 152 men with chronic SCI admitted to a rehabilitation center between 2017 and 2023. Participants were followed until death or December 2024 (median follow-up 62 months). Severe hypogonadism was defined according to European Male Ageing Study criteria. Cox proportional hazards models were used to assess the association between testosterone and mortality. Fully adjusted models included age, comorbidities, inflammatory status, functional independence, injury duration, age at injury, autonomic dysreflexia, body mass index (BMI), HDL, and testosterone-binding factors, including albumin. Prespecified parsimonious models (age + CCI or albumin) were also tested. Kaplan-Meier curves were compared by log-rank test and model discrimination was evaluated using Harrell's C-index.

resultsTwenty-four deaths (15.8%) occurred. Deceased patients had significantly lower cFT (48.9 vs. 85.4 pg/mL; p < 0.001) and lower serum albumin levels. In fully adjusted Cox models, lower cFT independently predicted mortality (HR 0.97 per pg/mL increase; 95% CI 0.95-0.98; p = 0.0139). Serum albumin was also strongly associated with mortality in multivariable models, confirming its role as a marker of nutritional and clinical frailty. The association between cFT and mortality remained robust in parsimonious models (HR 0.82 per 10 pg/mL increase; p = 0.001), including those adjusted for albumin. The age-cFT-CCI model showed good discrimination (Harrell's C-index 0.85). ROC analysis identified an internally derived threshold of 59.55 pg/mL (AUC 0.839), with significantly lower survival in men below this threshold (log-rank p < 0.0001). DISCUSSION AND

conclusionLow cFT independently predicts all-cause mortality in men with chronic SCI. These findings suggest that cFT may represent an integrative biomarker of systemic frailty beyond markers of nutritional and clinical status in this high-risk population and warrant confirmation in prospective multicenter studies.

Indexed as

HypogonadismSpinal Cord InjuriesTestosteroneAdultAgedChronic DiseaseHumansMaleMiddle AgedPrognosisRetrospective StudiesTestosteroneall‐cause mortalityandrogen deficiencycomorbidityhypogonadismspinal cord injurytestosterone

Identifiers

PMID42068005
PMCPMC13432611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.